Neutralizing anti-influenza B antibodies and uses thereof
AssigneesMedImmune, LLC, Humabs Biomed SA
InventorsNicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary McAuliffe, Davide Corti, Antonio Lanzavecchia
Life of this patent
Estimating the term…
Abstract
The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
Claims21
An isolated antibody or antigen binding fragment thereof that is capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages comprising a VH of SEQ ID NO.:
- 62 and VL of SEQ ID NO. 67.
A composition comprising an antibody or antigen binding fragment thereof according to claim 1 and 25 mM His and 0.15M NaCl at pH 6.0.
An isolated antibody or antigen binding fragment thereof that is capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages, wherein the antibody or antigen binding fragment thereof includes a set of six CDRs:
- HCDR-1, HCDR-2, HCDR-3, LCDR-1, LCDR-2, LCDR-3, in which the set of six CDRs is HCDR-1 of SEQ ID NO.:
- 145, HCDR-2 of SEQ ID NO.:
- 146, HCDR-3 of SEQ ID NO.:
- 147, LCDR-1 of SEQ ID NO.:
- 148, LCDR-2 of SEQ ID NO.:
- 149 and LCDR-3 of SEQ ID NO.:
- 150.
A composition comprising an antibody or antigen binding fragment thereof according to claim 11 and 25 mM His and 0.15M NaCl at pH 6.0.
Dependencies are inferred from the claim text.